A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Therapeutics
Nimbus Therapeutics
Vividion Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IFOM ETS - The AIRC Institute of Molecular Oncology
Accent Therapeutics
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
Marengo Therapeutics, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Gruppo Oncologico del Nord-Ovest
M.D. Anderson Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Blokhin's Russian Cancer Research Center
UNICANCER
Assistance Publique - Hôpitaux de Paris
Fate Therapeutics
Royal Marsden NHS Foundation Trust
Apollomics (Australia) Pty. Ltd.
Incyte Corporation
Incyte Corporation
University of Washington
Gustave Roussy, Cancer Campus, Grand Paris
Radboud University Medical Center